Showing 8871-8880 of 9128 results for "".
- Viscot Releases Prep-Resistant Ink Markerhttps://practicaldermatology.com/news/20130611-viscot_releases_prep-resistant_ink_marker/2459516/AllSkin Plus+ with Prep Resistant Ink is the first prep-resistant ink marker that offers maximum visibility and prep resistance on all skin tones. Its VIXL brilliant blue ink provides enhanced visibility even after prep and other fluids and remains visible up to 10 times longer than traditional ink.
- Suneva Selects Quinnova to Co-promote ReFissahttps://practicaldermatology.com/news/20130610-suneva_selects_quinnova_to_co-promote_refissa/2459520/Suneva Medical, Inc. selected Quinnova Pharmaceuticals, LLC to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin.
- Jurlique Product Supports the Underservedhttps://practicaldermatology.com/news/20130607-jurlique_product_supports_the_underserved/2459521/The Jurlique Ideas of Beauty Fund by Jurlique and Chrysalis supports the empowerment of women to lead better lives. Through the fund, Jurlique donates to organizations around the world committed to helping women. Proceeds from every
- Colorescience Expands Executive Teamhttps://practicaldermatology.com/news/20130531-colorescience_expands_executive_team/2459526/Colorescience appointed former SkinMedica CEO, Mary Fisher, who joins the brand in the same capacity. She will also serve on the Company's Board of Directors, which is chaired by David Hale of Hale BioPharma Ventures, LLC. Josie Juncal, Chief Commercial Officer for
- Valeant Pharmaceuticals to Acquire Bausch + Lombhttps://practicaldermatology.com/news/20130528-valeant_pharmaceuticals_to_acquire_bausch__lomb/2459529/
- FDA Rejects Valeant's Efinaconazole for Onychomycosishttps://practicaldermatology.com/news/20130528-fda_rejects_valeants_efinaconazole_for_onychomycosis/2459530/
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US special
- Clark Pharmaceuticals, Ferndale Healthcare Launch DerMendhttps://practicaldermatology.com/news/20130521-clark_pharmaceuticals_ferndale_healthcare_launch_dermend/2459534/Clark Pharmaceuticals partnered with Ferndale Healthcare to launch DerMend Moisturizing Bruise Formula. The formula is predicated on the idea that skin over 50 tends to get thinner and bruises more easily. Blood thinners, even those like low-dose baby aspirin, can cause skin to bruise. DerMend is de
- AMA Foundation Awards Research Grants To Study Issues Affecting Women In Medicinehttps://practicaldermatology.com/news/20130521-ama_foundation_awards_research_grants_to_study_issues_affecting_women_in_medicine/2459535/In 1850, the first medical institution in the world established to train women in medicine and offer opportunities of an MD opened their doors in Philadelphia. For those women, it was a chance to enter the medical world that routinely shut them out. While women today don't face such a task, importan
- AARS and AAP Release Acne Recommendationshttps://practicaldermatology.com/news/20130520-aars_and_aap_release_acne_recommendations/2459536/Evidence-based recommendations for the diagnosis and treatment of pediatric acne were recently published in Pediatrics. These recommendations were developed through the American Acne Rosacea Society (AARS) and endorsed by the American Academy of Pediatrics. The recommendations are a result of a two